Universal 3D printer bioink for Type 1 diabetes cell therapy

Uniink aims to develop a high-throughput 3D bioprinting method for producing consistent, insulin-secreting microspheres as a viable alternative to islet transplantation for Type 1 Diabetes treatment.

Subsidie
€ 150.000
2024

Projectdetails

Introduction

Type 1 Diabetes (T1DM) results from autoimmune destruction of pancreatic insulin-producing β-cells. Nowadays, insulin injections remain the leading therapeutic option. However, injection treatment fails to emulate the highly dynamic insulin release that β-cells provide.

Background

During the last years, 3D cell-laden microspheres have been proposed as a major platform for bioengineering insulin-secreting constructs for tissue graft implantation and as a model for in vitro drug screening platforms.

Current Challenges

Current microsphere fabrication technologies have several drawbacks:

  1. The need for an oil phase containing surfactants.
  2. Diameter inconsistency of the microspheres.
  3. High time-consuming processes, among others.

These technologies have widely used alginate for its rapid gelation, high processability, and low cost. However, its low biocompatible properties do not provide effective cell attachment.

Proposed Solution

To overcome these limitations, Uniink proposes a high-throughput 3D bioprinting methodology that employs an ECM-like microenvironment for effective cell-laden microsphere production. Crosslinking the resulting microspheres with tannic acid (TA) prevents collagenase degradation and enhances spherical structural consistency while allowing the diffusion of nutrients and oxygen.

Customization and Consistency

In addition, the approach allows customization of microsphere diameter with extremely low variability.

Conclusion

In conclusion, we will develop in Uniink a novel bio-printing procedure to fabricate large amounts of reproducible microspheres capable of secreting insulin in response to extracellular glucose stimuli. We expect that Uniink will represent a valid alternative to islet transplantation in T1DM patients, thus bringing cell therapy closer to application in humans.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-1-2024
Einddatum30-6-2025
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYApenvoerder

Land(en)

Spain

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

EIC Transition

Revolutionary silk-based bioink for 3D printing of ex vivo bone marrow models to advance drug development and personalized medicine

The SILKink project aims to develop a silk-based bioink for 3D printing bone marrow tissue models to enhance stem cell culture and advance drug development and personalized medicine.

€ 2.494.687
EIC Pathfinder

Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes

This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.

€ 3.885.462
EIC Pathfinder

High-throughput ultrasound-based volumetric 3D printing for tissue engineering

SONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research.

€ 2.999.625
EIC Accelerator

Beta-cell recovery to counter diabetes

DiogenX aims to cure Type 1 Diabetes by regenerating pancreatic beta-cells for autonomous insulin release, with plans to out-license the drug following human clinical proof by 2026.

€ 2.500.000